THERAPEUTICSMD INC (TXMD) Fundamental Analysis & Valuation

NASDAQ:TXMD • US88338N2062

2.3 USD
+0.05 (+2.22%)
Last: Mar 9, 2026, 05:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TXMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

TXMD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While TXMD seems to be doing ok healthwise, there are quite some concerns on its profitability. TXMD has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. TXMD Profitability Analysis

1.1 Basic Checks

  • TXMD had positive earnings in the past year.
  • TXMD had a positive operating cash flow in the past year.
  • TXMD had negative earnings in 4 of the past 5 years.
  • In the past 5 years TXMD reported 4 times negative operating cash flow.
TXMD Yearly Net Income VS EBIT VS OCF VS FCFTXMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • TXMD's Return On Assets of 0.78% is amongst the best of the industry. TXMD outperforms 80.83% of its industry peers.
  • With an excellent Return On Equity value of 1.10%, TXMD belongs to the best of the industry, outperforming 81.87% of the companies in the same industry.
Industry RankSector Rank
ROA 0.78%
ROE 1.1%
ROIC N/A
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TXMD Yearly ROA, ROE, ROICTXMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • TXMD's Profit Margin of 10.80% is amongst the best of the industry. TXMD outperforms 85.49% of its industry peers.
  • TXMD does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 10.8%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TXMD Yearly Profit, Operating, Gross MarginsTXMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. TXMD Health Analysis

2.1 Basic Checks

  • TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TXMD has about the same amount of shares outstanding.
  • TXMD has more shares outstanding than it did 5 years ago.
  • TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TXMD Yearly Shares OutstandingTXMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
TXMD Yearly Total Debt VS Total AssetsTXMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -32.92, we must say that TXMD is in the distress zone and has some risk of bankruptcy.
  • TXMD's Altman-Z score of -32.92 is on the low side compared to the rest of the industry. TXMD is outperformed by 87.05% of its industry peers.
  • TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -32.92
ROIC/WACCN/A
WACC9.37%
TXMD Yearly LT Debt VS Equity VS FCFTXMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 2.93 indicates that TXMD has no problem at all paying its short term obligations.
  • TXMD's Current ratio of 2.93 is in line compared to the rest of the industry. TXMD outperforms 51.30% of its industry peers.
  • TXMD has a Quick Ratio of 2.93. This indicates that TXMD is financially healthy and has no problem in meeting its short term obligations.
  • TXMD has a Quick ratio of 2.93. This is comparable to the rest of the industry: TXMD outperforms 54.92% of its industry peers.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.93
TXMD Yearly Current Assets VS Current LiabilitesTXMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TXMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 102.21% over the past year.
  • The Revenue has grown by 75.19% in the past year. This is a very strong growth!
  • The Revenue for TXMD have been decreasing by -48.72% on average. This is quite bad
EPS 1Y (TTM)102.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.74%
Revenue 1Y (TTM)75.19%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%43.33%

3.2 Future

  • TXMD is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.87% yearly.
  • Based on estimates for the next years, TXMD will show a small growth in Revenue. The Revenue will grow by 1.92% on average per year.
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TXMD Yearly Revenue VS EstimatesTXMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
TXMD Yearly EPS VS EstimatesTXMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

4

4. TXMD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 230.00, TXMD can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, TXMD is valued a bit cheaper than 76.68% of the companies in the same industry.
  • TXMD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.29.
  • Based on the Price/Forward Earnings ratio of 13.26, the valuation of TXMD can be described as correct.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TXMD indicates a rather cheap valuation: TXMD is cheaper than 86.01% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.60, TXMD is valued a bit cheaper.
Industry RankSector Rank
PE 230
Fwd PE 13.26
TXMD Price Earnings VS Forward Price EarningsTXMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, TXMD is valued cheaper than 87.56% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.87
EV/EBITDA N/A
TXMD Per share dataTXMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • TXMD's earnings are expected to decrease with -18.42% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TXMD Dividend Analysis

5.1 Amount

  • No dividends for TXMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TXMD Fundamentals: All Metrics, Ratios and Statistics

THERAPEUTICSMD INC

NASDAQ:TXMD (3/9/2026, 5:24:49 PM)

2.3

+0.05 (+2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-25
Inst Owners29.3%
Inst Owner Change2.46%
Ins Owners1.62%
Ins Owner Change0.04%
Market Cap26.61M
Revenue(TTM)2.80M
Net Income(TTM)302.00K
Analysts43.33
Price TargetN/A
Short Float %0.41%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 230
Fwd PE 13.26
P/S 9.52
P/FCF 12.87
P/OCF 12.87
P/B 0.97
P/tB 1.13
EV/EBITDA N/A
EPS(TTM)0.01
EY0.43%
EPS(NY)0.17
Fwd EY7.54%
FCF(TTM)0.18
FCFY7.77%
OCF(TTM)0.18
OCFY7.77%
SpS0.24
BVpS2.37
TBVpS2.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.73
Profitability
Industry RankSector Rank
ROA 0.78%
ROE 1.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 10.8%
GM N/A
FCFM 73.96%
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 684.77%
Current Ratio 2.93
Quick Ratio 2.93
Altman-Z -32.92
F-Score8
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.74%
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue 1Y (TTM)75.19%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%43.33%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
EBIT growth 1Y45.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y101.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.47%
OCF growth 3YN/A
OCF growth 5YN/A

THERAPEUTICSMD INC / TXMD FAQ

What is the ChartMill fundamental rating of THERAPEUTICSMD INC (TXMD) stock?

ChartMill assigns a fundamental rating of 4 / 10 to TXMD.


What is the valuation status of THERAPEUTICSMD INC (TXMD) stock?

ChartMill assigns a valuation rating of 4 / 10 to THERAPEUTICSMD INC (TXMD). This can be considered as Fairly Valued.


What is the profitability of TXMD stock?

THERAPEUTICSMD INC (TXMD) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for TXMD stock?

The Price/Earnings (PE) ratio for THERAPEUTICSMD INC (TXMD) is 230 and the Price/Book (PB) ratio is 0.97.


Can you provide the financial health for TXMD stock?

The financial health rating of THERAPEUTICSMD INC (TXMD) is 6 / 10.